Literature DB >> 16149096

Suppression of myoclonus in SCA2 by piracetam.

Anna De Rosa1, Pasquale Striano, Fabrizio Barbieri, Arturo de Falco, Carlo Rinaldi, Tecla Tucci, Salvatore Striano, Alessandro Filla, Giuseppe De Michele.   

Abstract

We report on a 30-year-old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12-18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations. Copyright (c) 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16149096     DOI: 10.1002/mds.20683

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

1.  Cerebrotendinous xanthomatosis: the effectiveness of high-dose piracetam for the treatment of cerebellar and sensorial ataxia.

Authors:  Ugur Uygunoglu; Aysegul Gunduz; Sukriye F Menku; Basak Yilmaz; Esra Hatipoglu; Cengiz Yalcinkaya; Sabahattin Saip; Hulya Apaydin
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

Review 2.  Spinocerebellar ataxia 2 (SCA2).

Authors:  Isabel Lastres-Becker; Udo Rüb; Georg Auburger
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 3.  Movement Disorders in Autosomal Dominant Cerebellar Ataxias: A Systematic Review.

Authors:  Malco Rossi; Santiago Perez-Lloret; Daniel Cerquetti; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2014-06-06

Review 4.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

Review 5.  The Multiple Faces of Spinocerebellar Ataxia type 2.

Authors:  Antonella Antenora; Carlo Rinaldi; Alessandro Roca; Chiara Pane; Maria Lieto; Francesco Saccà; Silvio Peluso; Giuseppe De Michele; Alessandro Filla
Journal:  Ann Clin Transl Neurol       Date:  2017-08-10       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.